Merck has agreed to discontinue a “predatory strategy” for the company’s Temodal (temozolomide) oncology brand in Austria that kept generics out of the market, including by supplying the brand below cost price, under commitments offered to the country’s competition watchdog.

South African’s Aspen Pharmacare has published first-half financials results that match a recent trading update, following a major reshaping. The new-look firm says it has “spent a long time building and a long time justifying building.”

After the European Commission adopted a preliminary assessment that Aspen Pharmacare “may have abused its dominant position by imposing unfair prices” for six mature oncology brands, the South African firm has outlined multiple commitments that would bring to a close a three-year Commission investigation across the EEA if adopted.